

# Jordi Bover

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8893439/jordi-bover-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79  
papers

1,551  
citations

21  
h-index

36  
g-index

87  
ext. papers

1,959  
ext. citations

3.9  
avg, IF

4.65  
L-index

#	Paper	IF	Citations
79	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 427-36	18.1	102
78	Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. <i>Kidney International</i> , <b>2017</b> , 92, 1343-1355	9.9	97
77	Vascular calcification in patients with nondialysis CKD over 3 years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 654-66	6.9	93
76	Adynamic bone disease: from bone to vessels in chronic kidney disease. <i>Seminars in Nephrology</i> , <b>2014</b> , 34, 626-40	4.8	82
75	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. <i>Kidney International</i> , <b>2016</b> , 90, 1184-1190	9.9	80
74	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 1815-20	4.3	77
73	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 319-331	18.1	67
72	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study. <i>Circulation</i> , <b>2020</b> , 141, 728-739	16.7	53
71	Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2017</b> , 8, 686-701	10.3	52
70	Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. <i>Kidney International</i> , <b>1994</b> , 45, 953-61	9.9	51
69	Pro: cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 345-51	4.3	46
68	When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. <i>Seminars in Nephrology</i> , <b>2014</b> , 34, 612-25	4.8	45
67	Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 161-74	6.9	41
66	Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. <i>Journal of Nephrology</i> , <b>2017</b> , 30, 677-687	4.8	38
65	Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. <i>Calcified Tissue International</i> , <b>2018</b> , 103, 111-124	3.9	34
64	News on biomarkers in CKD-MBD. <i>Seminars in Nephrology</i> , <b>2014</b> , 34, 598-611	4.8	33
63	Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. <i>Kidney International</i> , <b>2000</b> , 58, 1023-32	9.9	32

62	The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. <i>Kidney International</i> , <b>1994</b> , 46, 310-7	9.9	31
61	Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. <i>Kidney International Supplements</i> , <b>2011</b> , 1, 122-129	6.3	23
60	Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. <i>Nefrologia</i> , <b>2015</b> , 35, 28-41	1.5	23
59	Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. <i>Kidney International</i> , <b>1995</b> , 47, 1746-51	9.9	22
58	Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. <i>Nefrologia</i> , <b>2018</b> , 38, 476-490	1.5	20
57	Valvular heart disease and calcification in CKD: more common than appreciated. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 2046-2053	4.3	20
56	Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 2092-2100	4.3	19
55	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). <i>Nefrologia</i> , <b>2011</b> , 31 Suppl 1, 3-32	1.5	19
54	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 269-280	4.5	18
53	What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?. <i>World Journal of Nephrology</i> , <b>2016</b> , 5, 471-81	3.6	17
52	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. <i>Nefrologia</i> , <b>2016</b> , 36, 597-608	1.5	17
51	Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. <i>Nefrologia</i> , <b>2019</b> , 39, 227-242	1.5	16
50	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , <b>2016</b> , 29, 126-140	1.7	14
49	Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait?. <i>CKJ: Clinical Kidney Journal</i> , <b>2020</b> , 13, 513-521	4.5	13
48	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. <i>Nefrologia</i> , <b>2016</b> , 36, 597-608	0.4	13
47	The Modification of Diet in Renal Disease 4-calculated glomerular filtration rate is a better prognostic factor of cardiovascular events than classical cardiovascular risk factors in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , <b>2012</b> , 56, 1324-30	3.5	12
46	Calcimimetics in the chronic kidney disease-mineral and bone disorder. <i>International Journal of Artificial Organs</i> , <b>2009</b> , 32, 108-21	1.9	12
45	Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?. <i>Nefrologia</i> , <b>2016</b> , 36, 587-596	5.96	11

44	Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 313-23	3.3	11
43	Bone, inflammation and chronic kidney disease. <i>Clinica Chimica Acta</i> , <b>2020</b> , 506, 236-240	6.2	10
42	Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. <i>Nephron Clinical Practice</i> , <b>2011</b> , 118, c109-21		10
41	Update on the treatment of chronic kidney disease-mineral and bone disorder. <i>Journal of Renal Care</i> , <b>2009</b> , 35 Suppl 1, 19-27	1.6	10
40	Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. <i>Nefrologia</i> , <b>2018</b> , 38, 476-490	0.4	10
39	Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence. <i>Patient Preference and Adherence</i> , <b>2013</b> , 7, 1147-56	2.4	9
38	Bone Fragility Fractures in CKD Patients. <i>Calcified Tissue International</i> , <b>2021</b> , 108, 539-550	3.9	9
37	Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. <i>Nefrologia</i> , <b>2019</b> , 39, 227-242	0.4	8
36	The Non-invasive Diagnosis of Bone Disorders in CKD. <i>Calcified Tissue International</i> , <b>2021</b> , 108, 512-527	3.9	7
35	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 357	4.3	6
34	2010 - Guía de práctica clínica de la Sociedad Española de Diálisis y Trasplante de las alteraciones del metabolismo mineral y hueso de la enfermedad renal crónica (CKD-MBD). <i>Dialisis Y Trasplante</i> , <b>2011</b> , 32, 108-118		6
33	Tables for estimating the glomerular filtration rate using the new CKD-EPI equation from serum creatinine concentration. <i>Nefrologia</i> , <b>2014</b> , 34, 223-9	1.5	6
32	English-Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. <i>Kidney International</i> , <b>2020</b> , 98, 1352-1353	9.9	6
31	Is albuminuria a marker of arterial remodeling?. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 633-5	1.9	5
30	The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)-A Systematic Review. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	5
29	Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?. <i>Nefrologia</i> , <b>2016</b> , 36, 587-596		5
28	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. <i>Kidney International Reports</i> , <b>2020</b> , 5, 2178-2182 <sup>4.1</sup>		4
27	Recombinant PTH associated with hypercalcaemia and renal failure. <i>CKJ: Clinical Kidney Journal</i> , <b>2013</b> , 6, 93-95	4.5	4

26	Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. <i>Contributions To Nephrology</i> , <b>2008</b> , 161, 222-233	1.6	4
25	Kidneys also speak Spanish. <i>Nefrologia</i> , <b>2021</b> , 41, 225-226	1.5	4
24	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 366-374	4.5	4
23	Small steps towards the potential of preventive treatment of early phosphate loading in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 673-677	4.5	3
22	Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3-5 Not on Dialysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
21	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 736-745	6.9	3
20	Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease: Mineral-Bone Disorder-Related Aspects. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 642718	4.9	3
19	Bisphenol a Exposure and Kidney Diseases: Systematic Review, Meta-Analysis, and NHANES 03-16 Study. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	3
18	Vitamin D Receptor and Interaction with DNA: From Physiology to Chronic Kidney Disease <b>2016</b> , 75-116		2
17	PTH Receptors and Skeletal Resistance to PTH Action <b>2020</b> , 51-77		2
16	Control of phosphorus and prevention of fractures in the kidney patient. <i>Nefrologia</i> , <b>2021</b> , 41, 7-14	1.5	2
15	Hiporrespuesta o resistencia a la acción de la hormona paratiroidea en la enfermedad renal crónica. <i>Nefrologia</i> , <b>2021</b> , 41, 514-528	1.5	2
14	Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. <i>International Urology and Nephrology</i> , <b>2017</b> , 49, 689-700	2.3	1
13	Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. <i>Nefrologia</i> , <b>2021</b> ,	1.5	1
12	Relation Between PTH and Biochemical Markers of MBD <b>2020</b> , 103-116		1
11	The Parathyroid Type I Receptor and Vitamin D in Chronic Kidney Disease <b>2016</b> , 163-177		1
10	Osteoporosis in chronic kidney disease: A essential challenge. <i>Medicina Clínica</i> , <b>2021</b> , 158, 27-27	1	1
9	Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. <i>Nefrologia</i> , <b>2021</b> , 41, 514-528	0.4	0

8	Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. <i>Nefrologia</i> , <b>2021</b> , 42, 223-223	1.5	0
7	Acute Renal Failure Secondary to an Unusual Familial Metabolic Myopathy. <i>Nephron</i> , <b>2021</b> , 145, 199-204	3.3	0
6	Sobre la amplia difusi3 y autor3 de «los ri3ones tambi3 hablan espa3ol». <i>Nefrologia</i> , <b>2021</b> ,	1.5	
5	Osteoporosis in chronic kidney disease: A essential challenge. <i>Medicina Cl3nica (English Edition)</i> , <b>2022</b> , 158, 27-34	0.3	
4	New information on phosphate binder interactions with vitamin K. <i>Nefrologia</i> , <b>2020</b> , 40, 369-370	1.5	
3	New information on phosphate binder interactions with vitamin K. <i>Nefrologia</i> , <b>2020</b> , 40, 369-370	0.4	
2	Kidneys also speak Spanish. <i>Nefrologia</i> , <b>2021</b> , 41, 224-226	0.4	
1	Control of phosphorus and prevention of fractures in the kidney patient. <i>Nefrologia</i> , <b>2021</b> , 41, 7-14	0.4	